Impact of a community-based diabetes self-management program on key metabolic parameters

Main Article Content

Courtney Johnson
Janelle F. Ruisinger
Jessica Bates
Brian J. Barnes


Diabetes Mellitus, Pharmaceutical Services, Patient Education as Topic, Longitudinal Studies, United States


Objective: Characterize the impact of a pharmacist-led diabetes self-management program on three key metabolic parameters: glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), and mean arterial blood pressure (MAP) among employee health program participants.

Methods: A self-insured company in the Kansas City metropolitan area began offering a pharmacist-led diabetes self-management program to eligible company employees and their dependents in 2008. A retrospective pre-post analysis was conducted to determine if the program affected key metabolic parameters in participants by determining mean change after one year of participation.

Results: Among 183 program participants, 65 participants met inclusion criteria. All three key metabolic parameters were significantly reduced from baseline to one year of program participation: HbA1c decreased from 8.1% to 7.3% (p=0.007); LDL-C decreased from 108.3 mg/dL to 96.4 mg/dL (p=0.009); and MAP decreased from 96.1 to 92.3 mm Hg (p=0.005).

Conclusions: The pharmacist-led diabetes self-management program demonstrated significant reductions in HbA1c, LDL-C, and MAP from baseline to one year of program participation. Improvements were statistically significant and clinically relevant for each parameter. Previous studies indicate these reductions may cause reduced overall healthcare costs.

Abstract 1109 | PDF Downloads 1018


1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. 2011; (accessed November 15, 2012).

2. Fera T, Bluml BM, Ellis WM. Diabetes Ten City Challenge: final economic and clinical results. J Am Pharm Assoc (2003). 2009;49(3):383-391. doi: 10.1331/JAPhA.2009.09015

3. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash). 2003;43(2):173-184.

4. Garrett DG, Bluml BM. Patient self-management program for diabetes: first-year clinical, humanistic, and economic outcomes. J Am Pharm Assoc. 2005;45(2):130-137.

5. Bluml BM. "Project IMPACT: Diabetes" Care Model Improves Health Outcomes in Underserved Populations in 25 Communities with a High Incidence of Diabetes. Am Health Drug Benefits. 2013;6(9):560-561.

6. Chung N, Rascati K, Lopez D, Jokerst J, Garza A. Impact of a clinical pharmacy program on changes in hemoglobin a1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population. J Manag Care Pharm. 2014;20(9):914-919.

7. Iyer R, Coderre P, McKelvey T, Cooper J, Berger J, Moore E, Kushner M. An employer-based, pharmacist intervention model for patients with type 2 diabetes. Am J Health Syst Pharm. 2010;67(4):312-316. doi: 10.2146/ajhp090047

8. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm. 2006;63(21):2116-2122.

9. American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care. 2013;36(Suppl 1):S11-S66. doi: 10.2337/dc13-S011

10. Bluml BM, Watson LL, Skelton JB, Manolakis PG, Brock KA. Improving outcomes for diverse populations disproportionately affected by diabetes: Final results of Project IMPACT: Diabetes. J Am Pharm Assoc. 2014;54(5):477-485. doi: 10.1331/JAPhA.2014.13240

11. American Diabetes Association. Implications of the diabetes control and complications trial. Diabetes Care. 2003;26(Suppl 1):S25-S27.

Most read articles by the same author(s)